Adverts

Open Access Articles- Top Results for A-366,833

A-366,833

</th></tr>
A-366,833
240px
Systematic (IUPAC) name
5-[(1S,5R)-3,6-diazabicyclo[3.2.0]hept-6-yl]pyridine-3-carbonitrile
Clinical data
Identifiers
 7pxY
PubChem CID 9834234
ChemSpider 8009955 7pxY
ChEMBL CHEMBL239931 7pxY
Chemical data
Formula C11H12N4
200.239
 14pxY (what is this?)  (verify)

A-366,833 is a drug developed by Abbott, which acts as an agonist at neural nicotinic acetylcholine receptors selective for the α4β2 subtype, and has been researched for use as an analgesic, although it has not passed clinical trials.[1][2]

References

  1. ^ Ji, J.; Bunnelle, W.; Anderson, D.; Faltynek, C.; Dyhring, T.; Ahring, P.; Rueter, L.; Curzon, P.; Buckley, M.; Marsh, K. C.; Kempf-Grote, A.; Meyer, M. D. (2007). "A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo3.2.0-heptane alpha4beta2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models". Biochemical pharmacology 74 (8): 1253–1262. PMID 17854775. doi:10.1016/j.bcp.2007.08.010.  edit
  2. ^ Romanelli, M.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. (2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem 2 (6): 746–767. PMID 17295372. doi:10.1002/cmdc.200600207.  edit

Template:Navbox with collapsible sections

I


Lua error in package.lua at line 80: module 'Module:Buffer' not found.